-+ 0.00%
-+ 0.00%
-+ 0.00%

Personalis debuts Real-Time Variant Tracker data for NeXT Personal MRD at AACR 2026

PUBT·04/13/2026 10:00:29
Listen to the news
Personalis debuts Real-Time Variant Tracker data for NeXT Personal MRD at AACR 2026
  • Personalis outlined new clinical data for its NeXT Personal circulating tumor DNA minimal residual disease test scheduled for presentation at AACR Annual Meeting April 17-22, 2026.
  • Oral colorectal cancer results are set to show the assay can help predict response to neoadjuvant immunotherapy, supporting its role in treatment monitoring.
  • First data for Real-Time Variant Tracker will be presented, positioning the new MRD option as a tool to follow emerging therapy resistance once recurrence is detected.
  • Additional posters are expected to reinforce clinical utility in real-world use across solid tumors, strengthening Personalis’ commercial narrative for broader adoption.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604130600BIZWIRE_USPR_____20260413_BW770148) on April 13, 2026, and is solely responsible for the information contained therein.